Home
Company
Team
Technology
TARTIS rationale
TARTIS disease targets
Pipeline
OT-82
News
Home
Company
Team
Technology
TARTIS rationale
TARTIS disease targets
Pipeline
OT-82
News
OncoTartis has initiated OT-82 GLP Toxicology and Safety Pharmacology studies at Pharmaron, Ltd., US FDA-inspected Clinical Research Organization.
Previous
Next
OncoTartis has initiated OT-82 GLP Toxicology and Safety Pharmacology studies at Pharmaron, Ltd., US FDA-inspected Clinical Research Organization.
ira.turovets@gmail.com
2016-09-30T18:00:19+00:00
June 27th, 2016
|
Share This Story, Choose Your Platform!
Facebook
Twitter
Linkedin
Reddit
Tumblr
Google+
Pinterest
Vk
Email